Clinical Trial Update: Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating radiation therapy in combination with durvalumab for tumor-stage Cutaneous T-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Cutaneous T Cell Lymphoma | EARLY_Phase 1 | Status: WITHDRAWN